Invion June Quarter Appendix 4C | Is this Cancer Fighting Company a Buy?

3 Views

09/10/23

ASX Life Sciences Company, Invion (IVX), released their Appendix 4C on 22 July. Although Invion is operational cash flow positive, they do not have a product they are selling. Instead, they receive funding from RMW Cho Group to conduct the development of the Photosoft technology.
Shares on issue for Invion have increased from 150m to 5.5b in the ten years the company has been on the ASX. Hopefully, the heavy dilution of shareholders during this period has come to a completion.

► How to Find the BEST Small Cap Stocks
https://youtu.be/Funv6QDhMfw

► What is an Appendix 4C?
https://youtu.be/J7qzVtjFAfw

► Personal and Business Inquiries
kneppyinvests@gmail.com

► Social Media
Twitter: https://twitter.com/KneppyI